Terapie w programie lekowym:
Leki w katalogu chemioterapii:
Bevacizumab
Bevacizumabum
Bleomycin Sulphate
Carboplatin
Chlorambucilum
Cisplatinum
Cyklophosphamidum
Dacarbazinum
Denosumab
Docetaxelum
Doxorubicinum
Doxorubicinum Liposomanum Pegylatum
Epirubicinum
Etoposidum
Fluorouracilum
Gemcitabine
Ifosfamidum
Irinotecanum
Melphalanum
Methotrexatum
Paclitaxel
Tamoxifenum
Topotecanum Inj.
Trabectedin
Trastuzumabum I.v.
Vincristinum
Vinorelbinum
Badania kliniczne w Polsce - zobacz więcej w 🔍 wyszukiwarce
- ovarian cancer
- endometrial cancer
- » Patient Outcomes and Safety of Niraparib as Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, Ovarian Cancer. The First Real-World Evidence Study From Poland.
- » A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)
- » A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- » Assessment of the Concentrations of Functional Proteins as Potential Early Markers of Insulin Resistance in Women With Polycystic Ovary Syndrome
- » A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer